English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Human interleukin-15 (hIL15) exerts anticancer effects through the activitiesof lymphokine-activated killer (LAK) cells. However, its short half-life hindersits clinical application. Recombinant adeno-associated virus serotype 2 (rAAV2)is used for hIL15 gene transfer vectors, because of its low immunogenicity andlong-term gene expression in human clinical trials. SV40 T/t antigens are relatedwith many human epithelial cancers and are generally found in human breast cancer.In order to demonstrate the anticancer effects of hIL15 on SV40 T/t antigen-inducedbreast cancer, rAAV2-hIL15 was constructed and an SV40 T/t antigen-induced transgenicmouse breast cancer model was established. Our study showed that rAAV2-hIL15 couldexpress the hIL15 protein with anticancer bioactivity. In addition, rAAV2-hIL15could activate the cytotoxic activity of LAK cells in vivo. Furthermore, the rAAV2-hIL15successfully delayed cancer growth and eventually led to cancer cell death inSV40 T/t antigen-induced breast cancer transgenic mice. In summary, our studyindicates that rAAV2-hIL15 may be applied for cancer immunotherapy of SV40 T/tantigen-induced breast cancer.

Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice